Nayak SM

Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Nayak SM

An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder

Psychedelics Trials and Outcomes- A Closer Look.

5-HT&lt;sub&gt;1A&lt;/sub&gt; receptor blockade potentiates the subjective effects of DMT.

Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.

Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work.

Provider perspectives on challenges in treatment during psychedelic therapy.

Psychedelic Therapies: One Drug, Multiple Treatments Reply to Modesto-Lowe et al.

Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials.

Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.

Adverse Events Should Not Be Surprising in Psychedelic Research.

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use.

Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.

Practical considerations in the establishment of psychedelic research programs.

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?

Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.

Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study.

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.

Perceived risk of LSD use in the United States from 2015-2019: Are Americans assessing LSD’s risk profile more favorably?

Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.

A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities.

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.

5-HT<sub>1A</sub> receptor blockade potentiates the subjective effects of DMT.